ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,806 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentSchlierenMolecular Partners AG
Molecular Partners AG Logo
Verified· 4 sources

Molecular Partners AG

Summary

About the company

The company develops innovative therapeutic compounds, in particular DARPins, for diseases with high unmet medical need, with a focus on ophthalmology and oncology.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered5
DARPin therapeutics
DARPin therapeutics, a new class of multifunctional protein medicines; development of tailored active ingredients with high affinity, specificity, multispecificity and scalable manufacturing.
Radio-DARPin therapeutics
Radio-DARPin therapeutics for targeted alpha radiotherapy of tumors; precise delivery of radioactive payloads, reduction of nephrotoxicity, increased tumor uptake.
Switch-DARPin therapeutics
Switch-DARPin therapeutics for conditional, tumor-localized immunactivation; logic-controlled T-cell engagers and other multispecific candidates with target binding to tumor antigens.
Oncology pipeline therapeutics
Cancer therapeutics in clinical and preclinical development, including MP0712 for SCLC and neuroendocrine tumors, MP0726 for ovarian cancer, MP0317 for advanced solid tumors and MP0533 for AML.
Cooperation and development partnerships
Collaborations for the joint development, manufacturing and marketing of DARPin programs, in particular with Orano Med and previously with Novartis and AbbVie.
Reviews

Aggregated rating

Aggregated rating
4.9
of 5

Aggregated from 10 reviews across all connected sources

Sources
GGoogle4.910
★TrustpilotSoon
PProvenExpertSoon

Further sources are added continuously and factored into the ranQ Rating.

Press

Media

July 17, 2026Media
Forschung: Molecular Partners meldet Fortschritte mit MP0317 bei Gallengangkrebs
fuw.ch
July 1, 2026Media
Molecular Partners und Orano starten erste Patientenbehandlung
cash.ch
July 1, 2026Media
Erste Patienten erhalten Wirkstoff von Molecular Partners
punkt4.info
May 12, 2026Media
Quartalszahlen: Molecular Partners hat höheren Finanzierungsbedarf
fuw.ch
March 13, 2026Media
Einschätzung: Molecular Partners bringt mehr Wirkstoffe mit weniger Geld voran
fuw.ch

Knowledge

No knowledge articles yet

Once Molecular Partners AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Molecular Partners AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Molecular Partners AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Molecular Partners AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Wagistrasse 14
8952 Schlieren
Opening hours
Mon
08:00 - 17:00
Tue
08:00 - 17:00
Wed
08:00 - 17:00
Thu
08:00 - 17:00
Fri
08:00 - 17:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Corporation
UID
CHE-112.115.136
Founded
2004 · 22 years
Last commercial register change
June 24, 2026
Employees
101 to 500

Similar companies

IT
indie Technologies Switzerland AG
Schlieren
MA
Mabylon AG
Schlieren
LB
LimmaTech Biologics AG
Schlieren
IB
InterAx Biotech AG
Schlieren